ThyroSeq v3 在 Bethesda III 与 IV 类甲状腺结节中的机构应用经验
该研究回顾性分析了 2017 年 12 月至 2019 年 10 月间 415 例 Bethesda III 或 IV 类甲状腺细针穿刺样本的 ThyroSeq v3 检测结果与组织病理随访。结果显示总体良性呼叫率为 71%,AUS/FLUS 的良性呼叫率(82%)显著高于 FN/SFN(54%,P < .001),且 AUS/FLUS 的阴性预测值(99.5%)显著高于 FN/SFN(95.4%,P < .0294)。
要点
- ThyroSeq v3 在 AUS/FLUS 中良性呼叫率达 82%,可避免多数患者手术。
- AUS/FLUS 的阴性预测值为 99.5%,显著高于 FN/SFN 的 95.4%。
- 仅 5 例假阴性,其中 4 例为低风险肿瘤。
核心结论
- ThyroSeq v3 在 AUS/FLUS 中高良性呼叫率可避免多数患者手术,且揭示不确定结节的遗传复杂性。
研究设计与样本
- 回顾性机构经验分析,纳入 2017 年 12 月至 2019 年 10 月间 415 例 Bethesda III 或 IV 类甲状腺 FNA 样本。
- AUS/FLUS 251 例,FN/SFN 164 例;FNA 诊断与 ThyroSeq v3 结果及随访组织病理进行关联分析。
主要发现
- 415 例中 294 例(71%)为 ThyroSeq v3 阴性,121 例(29%)为阳性。
- AUS/FLUS 良性呼叫率为 82%(206/251),FN/SFN 为 54%(88/164),差异显著(P < .001)。
- 127 例有组织病理随访(阳性 96 例,阴性 31 例),其中良性 57 例,恶性 70 例(包括 NIFTP)。
- AUS/FLUS 的阴性预测值为 99.5%,FN/SFN 为 95.4%,差异显著(P < .0294);AUS/FLUS 恶性率 10%,FN/SFN 恶性率 30%。
临床怎么用
- 对 Bethesda III 类(AUS/FLUS)结节,ThyroSeq v3 阴性结果可高置信度排除恶性,支持保守随访。
- 对 Bethesda IV 类(FN/SFN)结节,ThyroSeq v3 阴性预测值较低(95.4%),需结合临床综合判断。
局限性
- 回顾性单机构研究,组织病理随访仅 available 于 127 例(31%),存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ThyroSeq v3 genomic classifier is a commercial molecular test that examines a wide spectrum of genomic alterations in a thyroid fine-needle aspiration (FNA) sample and reports test results as either negative or positive. The authors report their institutional experience with ThyroSeq v3. METHODS: Thyroid FNA specimens diagnosed as either atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) (Bethesda category III [Bethesda III] according to The Bethesda System for Reporting Thyroid Cytopathology) or follicular neoplasm/suspicious for follicular neoplasm (FN/SFN) (Bethesda IV) that had ThyroSeq v3 results available from December 2017 through October 2019 were retrieved for analysis. FNA diagnoses were correlated with ThyroSeq v3 results and follow-up histopathology. RESULTS: In total, 415 cases (AUS/FLUS, n = 251; FN/SFN, n = 164) were retrieved: 294 (71%) were reported as ThyroSeq v3-negative, and 121 (29%) were reported as ThyroSeq v3-positive. The benign call rate (BCR) of ThyroSeq v3 for AUS/FLUS (82%; 206 of 251 cases) was significantly higher (P < .001) than that for FN/SFN (BCR, 54%; 88 of 164 cases). Histopathologic follow-up was available for 127 cases (ThyroSeq v3-positive, 96; ThyroSeq v3-negative, 31), of which 57 were benign and 70 were malignant (including noninvasive follicular thyroid neoplasm with papillary-like nuclear features). The negative predictive value of ThyroSeq v3 was significantly higher for AUS/FLUS (99.5%) than for FN/SFN (95.4%; P < .0294), given malignancy rates of 10% for AUS/FLUS and 30% for FN/SFN. Forty-five unique combinations of genetic alterations were detected in the operated ThyroSeq-positive cases, and there were only 5 false-negative cases, comprised of 4 low-risk neoplasms. CONCLUSIONS: The high BCR of ThyroSeq v3 for AUS/FLUS prevents surgery in a majority of patients. The ThyroSeq v3 genomic classifier reveals the complexity of the genetic signature of indeterminate nodules.
引用
- Desai D, Lepe M, Baloch ZW, et al. ThyroSeq v3 for Bethesda III and IV: An institutional experience. Cancer Cytopathol. 2020. PMID: 33030808. doi:10.1002/cncy.22362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。